XML 23 R4.htm IDEA: XBRL DOCUMENT v3.20.1
Consolidated Statements of Income (Loss) - USD ($)
shares in Millions, $ in Millions
 3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Net revenues $ 4,357 $ 4,149
Cost of sales 2,294 2,293
Gross profit 2,063 1,856
Research and development expenses 221 261
Selling and marketing expenses 613 648
General and administrative expenses 304 292
Intangible assets impairments 649 469
Other assets impairments, restructuring and other items 121 1
Legal settlements and loss contingencies (25) 57
Other income (13) (6)
Operating (loss) income 191 134
Financial expenses, net 224 218
Income (loss) before income taxes (33) (84)
Income taxes (benefit) (59) 9
Share in (profits) losses of associated companies, net 1 4
Net income (loss) 25 (97)
Net income (loss) attributable to non-controlling interests (44) 8
Net income (loss) attributable to Teva 69 (105)
Net income (loss) attributable to ordinary shareholders $ 69 $ (105)
Earnings (loss) per share attributable to ordinary shareholders:    
Basic $ 0.06 $ (0.10)
Diluted $ 0.06 $ (0.10)
Weighted average number of shares (in millions):    
Basic 1,093 1,090
Diluted 1,096 1,090